Folgen
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/tackling-residual-risk-in-ascvd-and-ckd-9653
Summary
Inflammation plays a pivotal role in both cardiovascular and chronic kidney disease, making it a crucial target for reducing patient risk. In this focused 15-minute podcast, our experts break down the latest insights into how inflammation drives these conditions and explore innovative approaches to managing it.Listen to Dr. Ridker as he will delve into the critical role of inflammation in cardiovascular and chronic kidney disease, with a focus on the predictive value of hsCRP as a biomarker for ASCVD and CKD risk. Dr. Ridker explores emerging strategies to address inflammation, and how these advancements could potentially reduce cardiovascular risk and improve patient outcomes.
Learning Objective
Recognize the role of hsCRP as a biomarker in evaluating the risk of ASCVD and CKDIdentify the role of current and emerging agents, based on their mechanism of action, to target inflammation and potentially reduce cardiovascular risk
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse PractitionersÂŽ (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an independent medical educational grant from Novo Nordisk.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Integrate multidisciplinary management for patients with fibrosing ILDs to manage comorbidities and monitor for the need for specialty center referral
https://www.mycme.com/courses/circling-the-wagons-to-care-fibrosing-ilds-9649
Summary
Navigating the challenges of fibrosing ILDs requires a team approach. In this podcast, explore the "Dream Team" of healthcare professionals who collaborate to address the diverse needs of patients with IPF, SSc-ILD, and PPF. From pulmonologists to therapists and beyond, uncover the critical roles each plays in managing comorbidities, symptoms, and overall well-being. Gain valuable insights on when to refer to a specialized ILD center for comprehensive care.
Learning Objective
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Fehlende Folgen?
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/major-depressive-disorder-interventions-for-remission-9634
Summary
The goal of treating major depressive disorder (MDD) is complete remission. Unfortunately, residual symptoms, such as anhedonia and cognitive impairment, are common in patients with MDD and contribute to worse outcomes. Tailoring antidepressant therapy to individual patients can help to mitigate residual symptoms and promote complete remission.In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the risk-benefit profiles of available antidepressants and their efficacy for residual depressive symptoms. The faculty review the relative burden of side effects with different agents, the impact of therapies on cognitive function, and specific approaches to managing anhedonia.
This podcast/webcast was recorded and is being used with permission of the presenters.
Discuss the riskâbenefit profile of antidepressant medications and the potential impact on residual symptomsTailor MDD interventions to specific patient needs, based on the presence or risk of residual symptoms and using culturally sensitive communication, to achieve clinical remission
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse PractitionersÂŽ (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.50 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/primary-care-questions-on-moderate-to-severe-asthma-9617
Summary
Two experts from distinct clinical backgrounds â a primary care physician and a pulmonology PA â answer the top 5 questions primary care clinicians have about moderate-to-severe asthma. These questions come from clinician learners at Conversations in Primary Care (CPC) and Emerging Challenges and Clinical Updates in Primary Care (ECCU) live-virtual symposia from May through August, 2024.In just 15 minutes, this podcast/webcast covers the latest on:
New inhaler options: Albuterol/budesonide and smart therapy alternativesMontelukast: Weighing benefits against risks and boxed warningsBiomarkers: What to test and how to use the results to guide referralsBiologics: When to consider them and how to co-manage with specialistsPractical tips: Best practices for primary care clinicians in everyday asthma managementLearning Objectives
Evaluate patients with asthma to identify those with inflammatory phenotypes who are more likely to have exacerbations and severe diseaseEscalate care for patients with moderate-to-severe asthma uncontrolled on ICS-LABA
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0.25 hours of pharmacology.
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Physician Coaching by Professionally Trained Peers for Burnout and Well-Being. Jama Open Network 2024
Guest:
Susan Kuchera, MD
Program Director â Family Medicine Residency Program
Jefferson Health â Abington2. Association of Semaglutide With Tobacco Use Disorder in Patients With Type 2 Diabetes/ Target Trial Emulation Using Real-World Data/ Annals of Internal Medicine
Guest:
Richard Potter, MD
Resident â Family Medicine Residency Program
Jefferson Health â Abington3. Counterfit Ozempic JAMA
Guest:
Jasmine Walker, MD
Resident â Family Medicine Residency Program
Jefferson Health â AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:
1. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimerâs disease: a randomized, controlled clinical trial. Alzheimerâs Research & Therapy https://doi.org/10.1186/s13195-024-01482-z (2024) 16:122
Guest:
Philip Lieberman, MD
Resident â Family Medicine Residency Program
Jefferson Health â Abington2. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Guest:
Richard E. Pratley , MD
Medical Director at the AdventHealth Diabetes Institute
Senior Investigator, Diabetes Program Lead at the Translational Research Institute
3. Tirzepatide for Metabolic DysfunctionâAssociated Steatohepatitis with Liver Fibrosis
Guest:
Richard Potter, MD
Resident â Family Medicine Residency Program
Jefferson Health â AbingtonMedical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.
This Podcast Episode does not offer CME/CE Credit.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Identify ways to overcome provider and practice-based healthcare disparities in the management of patients with COPD
https://www.mycme.com/courses/impacting-copd-outcomes-challenges-and-opportunities-9534
Summary
Join Dr. Fernando Martinez as he welcomes Dr. David Au and Dr. Jamuna Krishnan to The NACE Clinical Highlights Show. This podcast highlights the research of Dr. Au and Dr. Krishnan, discussing the important translation of their research into pulmonology clinical practice.
Learning Objectives
At the conclusion of this activity, participants should be better able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Discuss the biology of menopausal vasomotor symptoms (VMS)Integrate new and emerging agents into the treatment of women with menopausal VMS, based on patient characteristics and preferences
https://www.mycme.com/courses/dd5-your-questions-on-menopausal-vasomotor-symptoms-9542
Summary
Dr. Leana Wen guides Dr. Genevieve Neal-Perry through five of your most common questions on menopausal VMS. Get a better understanding of the evolution in the science surrounding the biology of menopause, and discuss new and emerging non-hormonal treatment options for women with menopausal hot flashes and night sweats. Keep the conversation going with this, the third podcast in the series.
Learning Objectives
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an independent medical educational grant from Astellas Pharma Global Development, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Review evolving concepts in the understanding, evaluation, and treatments of severe asthma and their implications on management
https://www.mycme.com/courses/a-better-understanding-advances-in-severe-asthma-9530
Summary
In this CME/CE podcast, join NACE and the Association for Pulmonary Advanced Practice Providers as Nurse Practitioner Corinne Young and Dr. Diego Maselli take a deep dive into the latest advances in severe asthma treatment. Join in a dynamic discussion on groundbreaking research into IL-13 agents and mucus production, TSLP, mast cell activity, and more. Discover the expertsâ take on the latest evolutions in our understanding of asthma treatments, and gain practical insights into how these innovations are shaping clinical practice.
Learning Objectives
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours, which includes 0 hours of pharmacology.
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/recognizing-the-burden-of-residual-symptoms-in-mdd-9526
Summary
Early and effective treatment of major depressive disorder (MDD) is essential to prevent persistent residual symptoms, which are associated with worse outcomes. Evidence indicates that residual symptoms, such as impaired cognition, are underrecognized and undertreated in routine clinical care. Recognizing residual symptoms and the factors contributing to suboptimal treatment response is a critical first step to modifying management, with the goal of eliminating residual symptoms and achieving full remission.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss common residual symptoms and other signs of suboptimal treatment response, including the impact of antidepressant side effects and the efficacy of antidepressants for residual symptoms.This podcast/webcast was recorded and is being used with permission of the presenters.
This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse PractitionersÂŽ (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
2018 Guideline on the Management of Blood Cholesterol.2022 ACC Expert Consensus Decision Pathway.CLEAR Outcomes, CVOT studies, Risk Calculators.
https://www.mycme.com/courses/answering-your-questions-on-lipids-and-risk-9498
Summary
Thereâs no shortage of information on the management of lipids for the prevention of cardiovascular disease:Helping sort these and other topics out, Dr. James Underberg and Dr. Jessica Pena discuss the top 5 learner submitted questions/topics from the recent programs on non-statin lipid management in primary prevention of ASCVD.
Identify patients at high risk for ASCVD, based on risk factors and testing, who would benefit from additional lipid loweringIntegrate evolving evidence with guidelines and expert recommendations in the use of non-statin therapies for primary prevention of ASCVD in patients at high risk
Learning Objectives
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
Association of Black Cardiologists, Inc. (ABC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Association of Black Cardiologists, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse PractitionersÂŽ (AANP) through the joint providership of the National Association for Continuing Education (NACE) and ABC. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported in part by an educational grant from Esperion Therapeutics, Inc. and an independent educational grant from Novartis Pharmaceuticals Corporation.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/dd5-answering-your-questions-on-asthma-biologics-9499
Summary
In this activity, our asthma faculty, Dr. Diego Maselli, tackle the common, learner-submitted questions about the use of biologic agents in moderate-to-severe asthma. Five questions, and fifteen minutes on the clock.
This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hour (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Discuss the role of epithelial cytokines in the inflammatory response of asthma and other airway diseasesSelect appropriate agents to target the ongoing inflammatory cascade in patients with severe asthma
https://www.mycme.com/courses/dd5-your-questions-on-cytokines-in-asthma-9477
Summary
In this activity, moderator Corinne Young works with asthma expert Amanda Michaud to answer the common and remaining questions regarding inflammation in asthma, the role of TSLP and other alarmins, and the modulation of upstream and downstream cytokines with available and emerging biologic agents for asthma. Five questions in fifteen minutes â can they do it?!
Learning Objectives
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hour (which includes 0 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
NACE is excited to provide you with this podcast episode from our educational collaborator, The Association of Pulmonary Advanced Practice Providers (APAPP). APAPP is the first association of Advanced Practice Providers (APPs), both Nurse Practitioners and Physician Assistants, who work in the field of pulmonary medicine. APAPP's mission is to work together for the advancement of the profession and for the well-being of patients with pulmonary diseases. To learn more about APAPP and to get involved, please visit https://www.pulmapp.com.
Host
Corinne R. Young, MSN, FNP-C, FCCP
Director of APP and Clinical Services, Colorado Springs Pulmonary Consultants
President, APAPP, Colorado Springs, CO
Corinne Young is a Nurse Practitioner began working in the area of pulmonary disease in California in 2005. Since 2011, she has worked in a private pulmonary practice in Colorado Springs, Colorado. Involvement and the representation of advanced practice providers in the pulmonary world has been an important priority for Corinne. To that end, Corinne is the Founder and President of the Association of Pulmonary Advanced Practice Providers.
In addition to her work with APAPP, Corinne is currently one of ten NPs nationwide to become a Fellow of the American College of Chest Physicians. She works closely with the American College of Chest Physicians CHEST programs, and serves on the Interprofessional Team Network, Clinical Research Network, and on the Executive Programing Committee. Additionally, Corinne serves on the American Board of Internal Medicine Pulmonary Disease Board.This Podcast episode does not offer CME/CE Credit.
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/complex-connections-of-psychiatric-comorbidities-9505
Summary
The clinical assessment of psychiatric comorbidities, emphasizes the importance of a comprehensive diagnostic evaluation and personalized treatment plan. The recognition of genetic factors and their implications, allows psychiatrists and clinicians to enhance their management of psychiatric comorbidities when facing individuals with multiple mental health challenges.
In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the genetic underpinnings of mental health disorders and their psychiatric comorbidities, highlighting the role of heritability, genetic risk variants for depression, and polygenic burden in understanding complex psychiatric conditions. Dr. Maletic will delve into how genetic overlaps contribute to the co-occurrence of disorders such as anxiety and depression, and discuss the significance of gene-environment interactions and epigenetic changes in their development.This podcast was recorded and is being used with permission of the presenters.
This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse PractitionersÂŽ (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is not commercially supported.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/identifying-and-managing-treatment-resistant-depression-9471
Summary
âDifficult-to-Treatâ Depression (DTD) also referred as âtreatment-resistant depressionâ (TRD) are two terms used interchangeably but with distinct implications for therapeutic decisions and treatment strategies. In addition to focusing on symptom control, interventions for difficult-to-treat depression (DTD) should also address other factors, such as managing psychiatric and medical comorbidities, however, erroneous diagnosis and lack of treatment adherence had led to a variety of DTD outcomes.In this PsychTalk podcast/webcast episode, Dr. Gregory Mattingly and Dr. Vladimir Maletic discuss the evolving neurologic basis of depression and empower clinicians with convergent evidence about the pathophysiology and appropriate treatment options of âdifficult-to-treat depressionâ (DTD) and âtreatment-resistant-depressionâ (TRD) to inform therapeutic decisions.
This podcast/webcast was recorded and is being used with permission of the presenters.
Review the evolving genetic and neurologic basis of depressionDistinguish between âdifficult-to-treatâ and âtreatment-resistantâ depression to inform therapeutic decisions, and appropriate treatment options
Learning Objectives
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse PractitionersÂŽ (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is not commercially supported.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
-
For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
Discuss the biology of menopausal VMSIntegrate new and emerging agents into the treatment of women with menopausal VMS, based on patient characteristics and preferences
https://www.mycme.com/courses/new-approaches-to-menopausal-vms-9462
Summary
This CME podcast explores the latest advancements in managing menopausal vasomotor symptoms (VMS). Join Dr. Genevieve Neil-Perry as she discusses the biology of VMS, highlighting the role of KNDy neurons and neurokinin B. Discuss evidence-based treatments, including the new NK3 receptor antagonists and their clinical data. Gain practical insights into tailoring treatment to individual patient needs and addressing the unique challenges faced by women entering menopause.
Learning Objectives
Upon completion of this activity, learners should be able to:This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Creditsâ˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.50 contact hours (which includes 0.25 hours of pharmacology).
For additional information about the accreditation of this program, please contact NACE at [email protected].
Summary of Individual Disclosures
Please review faculty and planner disclosures here.
Disclosure of Commercial Support
This educational activity is supported by an independent medical educational grant from Astellas Pharma Global Development, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.
- Mehr anzeigen
